能倍乐 思力华噻托溴铵的副作用有哪些

Tiotropium bromide is a long-acting anticholinergic drug that selectively inhibits M3 receptors. It has the advantages of long maintenance of blood concentration and minimal side effects. Respimat is a long-acting bronchodilator that helps adults with chronic obstructive pulmonary disease (COPD) breathe easier.

Respimat has a certain therapeutic effect by helping patients open their airways, making it easier for air to enter and exit the lungs. In terms of usage, the recommended dose for adults is to inhale once a day through the Respimat inhalation device at the same time, taking 2 puffs each time. Patients should not overdose. Respimat is not only used when you encounter breathing problems. Normal use can also relieve persistent shortness of breath caused by the disease, helping to minimize the impact of the disease on daily life.

Like most drugs, Respimat, Tiotropium, and Slava also have some side effects, but Respimat is relatively safe. Dry mouth is a common side effect. Other uncommon side effects include headache, dizziness, high blood pressure, cough, difficulty sleeping (insomnia), irregular heartbeat (atrial fibrillation), feeling the heartbeat (palpitations), rapid heartbeat (tachycardia), and constipation.

Patients who are allergic to Respimat, Tiotropium, or its components are prohibited from using this drug. Some patients may develop rash, hives, sudden difficulty breathing (angioedema), swelling of the mouth and face, or other allergic reactions (such as a sudden drop in blood pressure or dizziness) after using Respimat, either alone or as part of a severe allergic reaction. If any of the above conditions occur, stop using this medicine and consult your doctor immediately. 

The above is an introduction to the side effects of Tiotropium Bromide. Since each patient's physical condition is different, the specific side effects vary from person to person. Please follow the doctor's instructions during treatment and use the medication correctly.

Recommended related hot articles: /newsDetail/85121.html